Month: August 2025

CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial was accepted and published in the international peer-reviewed open access scientific journal, Cells, in a special issue, “Cellular Mechanisms of Anti-Cancer Therapies” The manuscript, titled “Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy,” was authored by a group of oncology researchers in Turkey and the U.S. including MAIA scientists Sergei Gryaznov, Ph.D., Chief Scientific Officer and Ilgen Mender, Director of Biology Research, along with MAIA Scientific Advisory Board members Z. Gunnur...

Nearly 80% of employees admit to using unapproved AI tools, exposing businesses to risk and wasted ROI SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) — The AI revolution is well underway in the workplace, but a new survey from WalkMe, an SAP company and pioneer of the Digital Adoption Platform (DAP) category, reveals that employees are being left to navigate it on their own. The company’s second annual “AI in the Workplace Survey” finds that while workers are eager, most lack the support needed to use AI responsibly and effectively, fueling risk, wasted productivity, and lost ROI. Shadow AI is everywhereAI tools are flooding the workplace — but often without IT’s approval. 78% of employees say they use AI tools not provided by their employer, while more than half (51%) report conflicting guidance on when and how to use AI. This...

In its annual style issue, ‘Home & Style,’ Arhaus unveils a collection that brings the feeling of home to life through graceful forms, rich materials, and craftsmanship from around the worldBOSTON HEIGHTS, Ohio, Aug. 27, 2025 (GLOBE NEWSWIRE) — Arhaus (NASDAQ: ARHS), a leader in artisan-crafted home furnishings, today introduced its annual style issue, ‘Home & Style’, and Fall 2025 Collection now available at Arhaus.com and in over 100 showrooms nationwide. This year’s style issue celebrates the season’s guiding theme—Home is a Feeling—woven throughout a collection inspired by the quiet comfort of belonging: laughter in the next room, a seat saved just for you, and the spaces that make a house a home. “The expression of our new fall collection evokes a sentiment we can all relate to—that home is a feeling,” said John...

MANITOWOC, Wisc., Aug. 27, 2025 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today announced that it will participate in Singular Research’s Emerging Growth & Value Alpha Leaders Conference. The conference takes place September 10, 2025, at the AMA Executive Conference Center at 1601 Broadway (entrance on 48th Street) in New York City. Orion Chief Executive Officer Sally Washlow will deliver a company presentation and be available for one-on-one investor meetings throughout the event. The Orion presentation is scheduled for September 10, 2025, at 9:45 a.m. EDT. To view the presentation, please visit Singular Research Emerging Growth and Value Alpha Leaders Conference at...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 27, 2025 (GLOBE NEWSWIRE) — Critical One Energy Inc. (formerly Madison Metals Inc.) (“Critical One” or the “Company”) (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that, further to the press release issued on August 18, 2025, the Company has closed its oversubscribed, non-brokered financing and issued 5,001,999 units (the “Units”) at a price of CDN$0.60 per Unit for aggregate gross proceeds of CDN$3,001,199.40 (the “Private Placement”). Each Unit consists of one (1) common share in the capital of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each full Warrant entitles the holder thereof to purchase one Common Share for a price of CDN$1.00 for a period of eighteen (18) months from...

Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming monthsCOPENHAGEN, Denmark, August 27, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting data and company updates at numerous scientific and investor conferences throughout the second half of 2025. Further to presenting, Evaxion will engage with stakeholders, including potential partners, at the conferences. With events taking place in both the US, Europa and Asia, we will have many opportunities to liaise with global audiences as part of our strategy to identify potential partners and opportunities for both business partnerships and scientific collaborations. “As a scientific and innovative...

TAMPA, Fla., Aug. 27, 2025 (GLOBE NEWSWIRE) — Slide Insurance Holdings, Inc. (“Slide” or the “Company”) (Nasdaq: SLDE) today announced that its Board of Directors has authorized the repurchase of up to $75 million of the Company’s common stock. The authorization is effective immediately, has no time limit, and may be modified, suspended or discontinued at any time. “The initiation of our stock repurchase program is reflective of our strong confidence in our strategic direction, superior underwriting capabilities and well-capitalized balance sheet,” said Bruce Lucas, Chairman and Chief Executive Officer of Slide. “Slide has a very robust balance sheet from our recent IPO as well as better than expected net margins. As a result, our capital position is very strong and we will use it to repurchase common stock when we believe it is...

BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the BXCL501 arm While not the primary objective of the SERENITY At-Home trial, the preliminary results demonstrate continued effects and consistent benefit with repeat dosing across the course of the trial Following previously disclosed positive FDA feedback, BioXcel plans to submit a sNDA in Q1 2026 for expanded usage of BXCL501 in the outpatient setting without the supervision of a healthcare provider More than 2400 episodes of agitation were treated in the SERENITY At-Home trial suggesting a significantly larger potential market opportunity Company to host conference call at 8 a.m. EDT today NEW HAVEN, Conn., Aug. 27,...